Core Viewpoint - The release of the "Guidelines for the Protection of Trade Secrets in Biopharmaceutical Enterprises" in Zhejiang Province addresses the concerns of protecting core technologies and data in the biopharmaceutical industry, which is characterized by long R&D cycles and high investments [1][2] Group 1: Industry Context - The biopharmaceutical industry is a strategic emerging industry in Yuhang District, attracting leading enterprises in innovative drug development, high-end medical devices, and digital health, becoming a core engine for regional economic development [1] - The development of new drugs requires approximately ten years and investments of several billion, making the protection of sensitive data and formulas critical to prevent loss of years of effort [1] Group 2: Challenges Identified - A survey of 88 biopharmaceutical companies revealed three main pain points: the coexistence of high R&D investment with low-level protection, disconnection between high-level attention and grassroots execution, and contradictions between long collaborative processes and weak risk management [1] - Over 60% of companies reported inadequate technical protection, with sensitive data often unprotected and relying on basic confidentiality agreements without systematic management [1] Group 3: Guidelines Implementation - The guidelines are based on the "Civil Code" and "Anti-Unfair Competition Law," ensuring compliance while addressing actual business needs, covering management system construction, technical protection design, external collaboration risk control, and emergency rights protection [2] - Yuhang District has already established three commercial secret protection parks and 18 protection stations in Zhejiang Province, with 86 enterprises in Hangzhou designated as commercial secret protection points [2] - The release of the guidelines is seen as a new starting point, with plans for training, expert consultations, and digital platform development to ensure effective implementation and enhance the competitive edge of enterprises through confidentiality [2]
余杭为全省生物医药产业商业秘密保护提供“余杭经验”
Mei Ri Shang Bao·2025-12-07 22:19